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Background: Cardiovascular complications of obesity and diabetes are major health problems. Assessing their
development, their link with ectopic fat deposition and their flexibility with therapeutic intervention is essential. The
aim of this study was to longitudinally investigate cardiac alterations and ectopic fat accumulation associated with
diet-induced obesity using multimodal cardiovascular magnetic resonance (CMR) in mice. The second objective was
to monitor cardiac response to exendin-4 (GLP-1 receptor agonist).
Methods: Male C57BL6R mice subjected to a high fat (35 %) high sucrose (34 %) (HFHSD) or a standard diet (SD)
during 4 months were explored every month with multimodal CMR to determine hepatic and myocardial triglyceride
content (HTGC, MTGC) using proton MR spectroscopy, cardiac function with cine cardiac MR (CMR) and myocardial
perfusion with arterial spin labeling CMR. Furthermore, mice treated with exendin-4 (30 μg/kg SC BID) after 4 months
of diet were explored before and 14 days post-treatment with multimodal CMR.
Results: HFHSD mice became significantly heavier (+33 %) and displayed glucose homeostasis impairment (1-month)
as compared to SD mice, and developed early increase in HTGC (1 month, +59 %) and MTGC (2-month, +63 %). After 3
months, HFHSD mice developed cardiac dysfunction with significantly higher diastolic septum wall thickness
(sWtnD) (1.28 ± 0.03 mm vs. 1.12 ± 0.03 mm) and lower cardiac index (0.45 ± 0.06 mL/min/g vs. 0.68 ± 0.07
mL/min/g, p = 0.02) compared to SD mice. A significantly lower cardiac perfusion was also observed (4
months:7.5 ± 0.8 mL/g/min vs. 10.0 ± 0.7 mL/g/min, p = 0.03). Cardiac function at 4 months was negatively
correlated to both HTGC and MTGC (p < 0.05). 14-day treatment with Exendin-4 (Ex-4) dramatically reversed all these
alterations in comparison with placebo-treated HFHSD. Ex-4 diminished myocardial triglyceride content (−57.8 ± 4.1 %),
improved cardiac index (+38.9 ± 10.9 %) and restored myocardial perfusion (+52.8 ± 16.4 %) under isoflurane
anesthesia. Interestingly, increased wall thickness and hepatic steatosis reductions were independent of weight loss and
glycemia decrease in multivariate analysis (p < 0.05).
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Conclusion: CMR longitudinal follow-up of cardiac consequences of obesity and diabetes showed early accumulation
of ectopic fat in mice before the occurrence of microvascular and contractile dysfunction. This study also supports a
cardioprotective effect of glucagon-like peptide-1 receptor agonist.
Keywords: Cardiovascular magnetic resonance, Proton-magnetic resonance spectroscopy, Obesity, Diabetes, DIO mice
model, Longitudinal studyBackground
With the worldwide alarming increase in obesity, cardio-
vascular complications of obesity and diabetes are a major
public health problem. Indeed, obesity and diabetes are
closely inter-related risk factors for heart disease [1, 2].
First, there is a well-characterized association between
obesity and type 2 diabetes. Obesity leads to a 20-fold in-
crease in the prevalence of type 2 diabetes in women and
10-fold in men [1]. Second, chronic hyperglycemia may in-
duce diabetic cardiomyopathy [3–6]. It can lead to cardiac
damage and microvascular complications independently
of coronary artery disease and hypertension. Third, an in-
verse correlation between myocardial blood flow reserve
and poor glycemic control in type 2 diabetes has been
clearly demonstrated [7].
Ectopic fat deposition often results from dysfunction
of subcutaneous adipose tissue and imbalance between
fatty acid uptake and oxidation rate. It is considered to
contribute to organ dysfunction via an effect commonly
described as lipotoxicity [8]. Many studies have reported
that lipid accumulation in the heart and in the liver in-
creases in obese and diabetic mice, and that this increase
is associated with diastolic function impairment [9–11].
In addition, many studies in animal models have demon-
strated that cardiac ectopic fat accumulation is causally
linked with cardiac dysfunction [12, 13]. Glucotoxicity
and lipotoxicity are both well recognized initiators of
heart diseases [13, 14], but their chronological effect
in vivo under different metabolic conditions still needs
to be clarified.
For this reason, there is increasing need for new methods
to better characterize cardiac alterations and ectopic fat
development and to analyze the impact of new poten-
tial treatments against these complex and interrelated
metabolic conditions.
Cardiovascular magnetic resonance (CMR) techniques
are potentially valuable tools, which have shown excel-
lent ability to provide useful data on fat distribution
and cardiac function in humans [15, 16]. In mice, pro-
ton MR spectroscopy (1H-MRS), in particular, gives
access to the molecular content of cardiac or hepatic
triglycerides (TG), and it has been shown to provide
good accuracy when compared to gold standard bio-
chemical assays [11, 17]. Considering adverse effects
of diabetes on microvessels, there is strong evidencesuggesting that the integrity of the vascular endothe-
lium is altered in this disease eventually resulting in
myocardial injury [18, 19]. Moreover, Naresh et al.,
showed reduced myocardial perfusion reserve using
dual-contrast first-pass CMR sequence in mice after
24 weeks of high-fat diet. However, whether this re-
duction is associated to high-fat diet-induced obesity
or diabetes development hasn’t been explored so far.
Accordingly, microvascular abnormality deserves specific
mention, and better knowledge on functional alterations
of the coronary microcirculation may in the future serve
in evaluating and monitoring potential therapeutic regula-
tion approaches of endothelial dysfunction in T2D. CMR
is playing an expanding role in the non-invasive assess-
ment of myocardial blood flow. Arterial spin labeling
(ASL) CMR techniques in particular appear as a powerful
and direct tool for the assessment of murine myocardial
perfusion without any injection of contrast agents
[20–23]. They can further be performed repeatedly and
are therefore a good candidate for longitudinal tracking.
To date there are few longitudinal multi-modal in vivo
studies combining the assessment of all these parameters
to study the disease progression. Here, we implemented
a protocol providing combined assessment of several pa-
rameters including global myocardial function, ectopic
accumulation of triglycerides in non-adipose tissues (heart
and liver steatosis) and myocardial perfusion and applied
it to a HFHSD-induced mouse model of obesity and dia-
betes. The combination of the entire set of advanced CMR
and hepatic techniques into a single protocol was possible
mainly by using the rapid cine-ASL perfusion CMR ap-
proach and a two-slice cine-CMR sequence that was
found to provide good global function approximations
earlier [24]. The 30–45 min protocol was repeated in a
4-month longitudinal follow-up during development of
glucose intolerance in the HFHSD mice. The HFHSD
model was chosen because it is considered to mimic best
the human western diet with comparable consequences
on body composition changes, impaired glucose tolerance
and insulin sensitivity, hepatic steatosis, cardiac structure
and function [25].
In an additional session, we assessed the effects of
Exendin 4 (GLP-1 receptor agonist), administered during
a short time (15 days, with small weight effect) to the
animals in order to assess its effect on cardiac perfusion
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total body fat. Incretins, glucagon-like peptide-1 (GLP-1)
receptor agonists are new pleiotropic drugs widely
used in type 2 diabetic patients. These drugs actually
improve glycemic profile, decrease glucagon secretion
and increase satiety via their action on central nervous
system. Besides, emerging evidence suggests beneficial
effects of these molecules on cardiac structure and func-
tion. GLP-1 and GLP-1 receptor agonists would indeed
decrease both inflammatory state [26] and blood pressure
[27], improve endothelial [28, 29] and cardiac function in
ischemia reperfusion infarction model [30]. However,
short time effect of Exendin 4 on cardiac function and on
ectopic fat development has been rarely studied [31, 32].Methods
Animals
All animal procedures were approved by the Animal
experiment ethic committee of Aix-Marseille Univer-
sity (n°40-10102012) and were in conformity with the
European Convention for the protection of animals
used for experimental purposes.
Fifty-six C57BL/6 J Rj eight-week-old male mice were
purchased from Janvier labs (France). Animals were housed
2 weeks before experimentation in a controlled environ-
ment under standard laboratory conditions: a 12 h-12 h
light–dark cycle and room temperature maintained at
24 °C. The mice had ad libitum access to water and food.Diet and exendin-4 treatment experimental protocol
The study was divided into three experimental protocols
(Fig. 1). In the first protocol, we performed a longitu-
dinal follow-up of glucose homeostasis alteration in ten
mice fed a high-fat high-sucrose diet (HFHSD, 35 % fat,
34 % carbohydrate, 22 % protein) for 16 weeks compared
to ten mice fed a standard chow diet (SD, 60 % carbohy-
drate, 3 % fat, 16 % protein). Composition of the diet is
detailed in Additional file 1. In the second protocol, we
performed another monthly longitudinal follow-up of
cardiac alterations and ectopic fat deposition including:
CMR, liver MRS and whole body fat mass MRI. For this
purpose, ten mice were fed a SD, and 10 mice were fed a
HFHSD for 16 weeks. In the third protocol, 12 mice
were fed a SD, and 24 mice were fed HFHSD during 16
weeks and were then treated with Exendin-4 (30 μg/Kg
SC BID) or placebo (phosphate-buffered saline SC BID)
for 14 days. The MR protocol as described later was per-
formed at 4-month post diet and after 14 days of
exendin-4 treatment. Glucose tolerance test and insulin
measurement were performed at the end of the experiment.
Weight and glucose level were measured every month in
each experimental protocol.CMR measurements
All CMR scanning was performed on a Bruker Biospec
Avance small animal MRI system equipped with a 4.7
Tesla magnet (Bruker, Ettlingen Germany). CMR and 1H
MRS were both performed using a proton volume reson-
ator (diameter 60 mm, homogeneous length 80 mm)
and an actively decoupled 15 mm surface receive coil
(Rapid Biomedical, Wurzburg, Germany). The animals
were positioned prone on the surface coil. For the CMR
protocol, the animal was placed with the heart at the
center of the surface coil. For the subsequent liver MRS
analysis the animal was repositioned with the abdomen
at the coil center.
Before the experiments, mice were sedated in an in-
duction chamber by inhalation of a mix of 3 % isoflurane
and 2 L/min pure oxygen-flow. During CMR, inhalation
anesthesia was maintained at 1–2 % of isoflurane in
pure oxygen at 0.6 L/min using a dedicated vaporizer
(Ohmeda/General Electric, Milwaukee, WI, USA) so as to
obtain regular breathing frequencies in the range of 90–100
breaths per minute. Respiration was monitored using a
pressure sensor connected to an air-filled balloon posi-
tioned under the abdomen. Body temperature was moni-
tored using a rectal probe and maintained at 37 °C using a
heating blanket with hot water circulation. The electrocar-
diogram (ECG) signal was monitored by placing two sub-
cutaneous electrodes in the upper limbs of the mice. The
electrodes were connected to an ECG trigger unit (Rapid
Biomedical, Rimpar, Germany) to record the signal and to
trigger the CMR sequence. The respiratory signal was used
in addition to the ECG trigger for gating the MRS scans.
In vivo cardiac function (cine-CMR)
The assessment of myocardial mass and function by
cine-CMR was performed according to the hemisphere
cylinder model using one short axis area measurement
and one long axis length for volume approximation. This
model has recently been validated as one of the best
methods to assess cardiac function in a reduced scan- and
post-processing time [24]. A FLASH cine-CMR sequence
(37 phases, slice thickness 1 mm, in-plane resolution 234 x
234 μm2, TR = 5.1 ms, TE = 1.4 ms, two averages, duration
3 min per slice) was used to acquire three perpendicular
views (2-chamber, 4-chamber and mid-LV short axis).
Image segmentation and data analysis were performed
using an in-house developed program running under
IDL environment (ITT, Boulder, CO, USA). Epicardium,
endocardium, and left ventricular lengths were manually
delimited in both systole and diastole to obtain needed data
for volume approximation as described previously [33].
In vivo myocardial perfusion (Arterial spin labeling CMR)
Myocardial blood flow was quantified using a modified
version of the cine-ASL technique, as described previously
Fig. 1 Flowchart of mice in different diet groups and treatment. HFHSD mice (C57BL6J on High fat high sucrose diet) and SD mice (C57BL6J on
control diet) were kept on diet for 16 weeks in the first experiment (glucose homeostasis study), both glucose and insulin tolerance tests were
performed every month in order to determine time of impaired glucose homeostasis. In the second experiment (chronological study), a magnetic
resonance (MR) examination was performed every month and intraperitoneal glucose tolerance test was done at the end of experiment (16 weeks)
before sacrifice. In the third experiment (experimental study), SD mice were kept on standard diet only for 16 weeks until MR examination and IPGTT.
Mice fed HFHSD underwent MR examination and IPGTT at 16 weeks, before treatment with exendin-4 or physiological serum during 14 days and then
underwent once again MR examination and IPGTT after treatment
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TR =1.64/8 ms, field of view = 25 mm x 25 mm, matrix
size = 128 x 64, resolution = 0.195 mm x 0.391 mm, ex-
citation pulse duration = 0.5 ms, inversion pulse duration =
6 ms, imaging slice thickness = 1.5 mm, labeling slice
thickness = 2.5 mm, Nechoes = 10, Ncine = 30. Images
analyses were performed using a home-made program
running in an IDL environment (ITT, Boulder, CO,
USA) which generates perfusion maps. Using these maps,
we quantified myocardial perfusion in mL/g/min.
In vivo triglyceride accumulation (MR spectroscopy)
Cardiac 1H MR spectra were acquired using an ECG- and
respiratory-gated Point Resolved Spectroscopy (PRESS)
sequence at the systolic phase to determine the molecular
content of water appearing at 4.7 ppm and of triglyceridesat 1.3 ppm. The parameters were as follows: voxel size 1 x
1 x 2 mm3, echo time 11 ms, repetition time ranging be-
tween 700 and 1000 ms depending on the breath rate,
number of averages (NA) 512. A second scan was ac-
quired to obtain an unsaturated water peak as reference
(TR = 5 s, NA = 64). Cine-CMR images in short-axis and
4-chamber views were used for voxel positioning in the
basal region of the septum (Fig. 3b) far enough from the
pericardial fat to avoid fat contamination.
The same sequence with slightly modified parameters
(TE = 11 ms, NA = 128, and TE = 11 ms TR = 5 s, NA =
64, for the reference scan, respiratory gating) and a larger
voxel size (2x2x2 mm3) was used for liver MRS. The voxel
was placed in the anterior part of the liver (Fig. 3a).
The TR for MRS measurements of tissue TG content
ranged between 700 and 1000 ms with most experiment
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saturation has occurred with possible different TRs, we
fitted triglyceride peak in both saturated spectra, and un-
saturated reference spectra for heart an liver. Ratio of
TG concentration in saturated spectra over TG concen-
tration in unsaturated spectra is about 0.96 ± 0.15 in
average in heart and liver. Therefore, underestimation of
TG is inferior to 5 % and variation from one experiment
to the other is weak.
Data fitting and analysis were performed using AMARES
time-domain fitting routines from the MRUI package
(http://www.jmrui.eu/, Fig. 3c) with a home-made software
interface [34]. The TG/Water ratio was calculated to obtain
the triglyceride concentration. Due to the short echo time,
potential impact of T2 on the signal amplitudes was
neglected.In vivo whole body fat mass (Magnetic resonance imaging)
For a quantitative map of adipose tissue distribution,
whole-body scanning was performed using the volume
resonator for radiofrequency transmit and receive. Sixty-
four transverse slices were obtained across the animal
body length excluding the tail with a slice thickness of
1.25 mm. High-resolution three-dimentional (turbo-spin
echo) sequence was used with the following parameters:
5.530 ms echo time; 77.85 ms effective echo time; 300 ms
repetition time; 2 averages; 40x40x80 mm field of view;
and 128x128x64 matrix size [35]. Subcutaneous (SCAT)
and visceral adipose tissue (VAT) were assessed using an
automatic segmentation method based on a pixel intensity
analysis of MR images [36].Glucose homeostasis and triglyceride measurements
using biochemical analysis
Mice were sacrificed at the end of the three experimen-
tal protocols. Blood and tissue were collected when mice
were sacrificed after an overnight fasting for possible ex-
vivo experiments. Plasma samples were used to analyze
insulin levels using an ELISA kit (Alpco, Salem, USA)
and plasma triglycerides using Triglyceride Assay Kit
(Chemical Company, CAYMAN). Furthermore, experi-
mental protocol number 1 was specifically performed to
analyze glucose homeostasis with IntraPeritoneal Glu-
cose Tolerance Test (IPGTT) and Intraperitoneal Insulin
Tolerance Test (IPITT) exploration alone, independently
of possible repeated MR exploration-induced stress or
anesthesia as it may affect in short-term metabolic pa-
rameters such as glucose and insulin [37].
IPGTT was also performed, in the second protocol at
the end of experiment, after MR explorations. In the
third protocol, IPGTT was performed after MR explor-
ation as well, 16-week post-diet, and after Exendin-4
treatment.In IPGTT and IPITT, a bolus of glucose (1 mg/g) or
insulin (0.75 mU/g) was injected into the peritoneal
cavity, after an over-night fasting period. Blood glucose
level was measured using commercial glucometer (Accu-
Check Active Glucometer, Roche, Basel, Switzerland)
before glucose or insulin injection (0 min) and 15 min,
30 min, 60 min, and 120 min after injection.
After sacrifice, TGs were assayed in vitro in the plasma,
liver and heart. In the tissues, lipids were extracted from
110 mg of liver tissue or 110 mg of heart tissue using
chloroform/methanol as outlined by Folch et al. [38]. Tri-
glycerides were measured using standard colorimetric assay
(Triglyceride Assay Kit, Chemical Company, CAYMAN).
Triglycerides were expressed as mg/dL.
Statistical analysis
All data are presented as means ± SEM. Statistical analysis
was performed with GraphPad Prism 5.01. Two-way
ANOVA test with repeated measures was performed
for all parameters such as weight, CMR cardiac parameters,
ectopic lipid deposition, cardiac perfusion, and intraperito-
neal glucose tolerance test, to test disease progression
including effect on time and diet. Therefore, multiple
comparisons test using Sidak-Bonferroni method has
been achieved to show differences between groups at
each time point.
Linear regression was used to evaluate the relation
between ectopic fat deposition and cardiac parameters.
The effect of exendin-4 treatment was analyzed with paired
t-test or non-parametric Wilcoxon test when appropriate.
Multivariate analysis was achieved using Statview 5.0 to
analyze the effect of independent effect of treatment on
cardiac improvement and steatosis reduction. Values of
p <0.05 were considered statistically significant.
Results
Evolution of weight and glycemia
Mice fed with HFHSD became obese. They displayed
significantly higher body weight (47.3 ± 0.7 g vs. 32.9 ±
0.1 g, p = 0.0006) and abdominal fat (13.4 ± 0.8 mm3 vs.
3.8 ± 0.4 cm3, p = 0.0002) after 4 months of diet com-
pared to mice fed with SD. These significant weight gain
and abdominal fat increase differences were already ob-
served after one month of HFHSD (Fig. 2a and b).
HFHSD mice also displayed significantly elevated area
under the curve of glucose level during intraperitoneal
glucose tolerance test (IPITT) (Fig. 2c) showing impaired
glucose tolerance and elevated fasting plasma glucose
(Fig. 2d) at 2 months compared to SD mice. Fasting blood
glucose level exceeds 2.4 g/L at 3 months (2.6 ± 1.1 g/l) in
the HFHSD group suggesting type 2 diabetes status [39].
Intraperitoneal glucose tolerance test (IPGTT) showed
impaired glucose secretion resulting in significantly elevated
area under the curve (AUC) of glucose in the HFHSD
Fig. 2 Characterization of HFHSD-induced obesity model. Mice fed the HFHSD became significantly obese (a) and had an increased abdominal
fat volume at the first time point (b). Time course of intraperitoneal insulin tolerance test revealed significantly impaired glucose tolerance (c) and
higher fasting plasma glycemia (d) in the HFHSD group at 2 months post-diet. Examples of intraperitoneal glucose test tolerance at 1-month
(glucose administration arrow, 1 g/kg) (e), and intraperitoneal insulin tolerance test (insulin administration arrow, 0.75 mU/g) at 1 months (f)
and 2-month (g) post diet. Data are means ± SEM. Two-way Anova test with repeated measures has been performed to assess differences
*P < 0,05; **p < 0,005; ***p < 0,0005 vs SD
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(Fig. 2e). At the same time (1 month) AUC of glucose dur-
ing IPITT was not different between HFHSD and SD mice
(Fig. 2f), but became significantly higher at 2 months post-
diet (Fig. 2g).Ectopic fat accumulation at early time points
Triglycerides assessed with MRS were significantly higher
in the liver at one month post-diet and further increased
until it reached 42 ± 8 % for obese mice compared to
1.88 ± 0.27 % for SD mice at 4 months (Fig. 3a).
Although there seems to be higher myocardial trigly-
ceride content in HFHSD groups at the beginning, this
difference did not reach significant value before 2-
month post-diet and remained statistically elevated
until the CMR examination at 4 months in obese mice
(0.82 ± 0.08 %) compared to lean mice (0.40 ± 0.09 %)
(Fig. 3b). This atypical difference at baseline is probably
due to variability between mice.Myocardial and hepatic TG levels were significantly
linked to weight, glycemia and AUC glucose during GTT
(Fig. 3c).
Triglyceride level evaluated by biochemical assay in bi-
opsies obtained after mice sacrifice (4-month) showed a
significant higher triglyceride content in both heart and
liver, which is consistent with MR spectroscopy results.
(Additional file 2)
Evolution of cardiac function during HFHSD
HFHSD mice exhibited higher diastolic septum wall
thickness (sWtnD) (1.28 ± 0.03 mm vs. 1.12 ± 0.03 mm,
p = 0.002) (Fig. 4a) starting at 3 months post-diet com-
pared to mice fed with a standard diet, and decreased
septum percent fractional shortening (sFS) (40.3 ± 3.4 %
vs. 54.6 ± 6.2 %, p = 0.01) at 4-month post diet (Fig. 4b).
Mice fed a HFHSD presented a significant alteration
of cardiac index from 3 months post-diet compared to
control mice (0.52 ± 0.04 μL/min/g vs. 0.74 ± 0.07 μL/
min/g, p = 0.01) (Fig. 4c). This difference could be
Fig. 3 Myocardial and hepatic steatosis assessed with 1H-MRS. Hepatic (a) and myocardial (b) fat were followed-up during 4 months. Myocardial
and hepatic steatosis were inter-correlated at M4 (c), and correlated to weight, glycemia and area under the curve (AUC) of glucose at M4. Vol-
ume of interest was positioned in the anterior part of the liver for hepatic triglyceride content quantification (d), and in the interventricular
septum for myocardial triglyceride content quantification (e). PRESS sequence was applied to determine molecular content of water and triglycer-
ide. Chemical shifts appear at 4.7 ppm in the spectra for water, and 1.3 ppm for triglycerides. AMARES algorithm fitting peak line shape has been
used for spectra analysis (f). Two-way Anova test with repeated measures has been performed to assess differences. Data are mean ± SEM.
*P < 0,05; **p < 0,005; ***p < 0,0005 vs SD
Fig. 4 Cardiac function parameters using hemisphere cylinder model. Obese mice increased the diastolic septum wall thickness (WthD) (a) and
decreased septum fractional shortening (sFS) (b) at 3-month post diet. Cardiac index (CI) was altered at the same time point (c). Left ventricular
mass (LVmass) (d), ejection fraction (EF) (e), and stroke volume (SV) (f) did not change during diet. Two-way Anova test with repeated measures
has been performed to assess differences. Data are mean ± SEM. *P < 0,05; **p < 0,005
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in HFHSD groups (data not shown). The obese group
exhibited progressive reduction of cardiac index and
fractional shortening during 4 months of diet com-
pared to control mice, which, in contrast, showed con-
stant levels of these parameters over time, together
with a comparable expansion of the left ventricular
mass in both groups (Fig. 4d).
Furthermore, cardiac function parameters at 4-month
post-diet were correlated to both hepatic and myocardial
fat content (p <0.05) (Table 1).
Other cardiac function parameters such as ejection
fraction and stroke volume did not change at this rela-
tively early time point (Fig. 4e and f ).Fig. 5 Myocardial perfusion using Cine-ASL (Arterial Spin Labeling)
technique. Typical example of myocardial perfusion maps in mice
fed HFHSD (left) and control mice fed SD (right) (a). Temporal variation
in myocardial perfusion during 4 months in HFHSD and SD mouse
groups (b). Two-way Anova test with repeated measures has been
performed to assess difference *p <0,05HFHSD-fed mice displayed changes in myocardial
perfusion at rest
Anova test has not shown myocardial perfusion change
during 4 months of HFHSD. However, we undoubtedly
observed a significant difference in myocardial perfusion
at 4-month post-diet in obese mice compared to control
mice as shown in representative images (Fig. 5a). Quan-
titative analysis of myocardial perfusion (Fig. 5b) showed
a tendency to hypoperfusion at 4-month post-diet.
Unpaired t-test of data at 4 months post diet alone
confirmed lower perfusion observed in mice fed with
HFHSD compared to mice fed with SD (7.5 ± 0.8 mL/g/
min vs. 10.0 ± 0.7 mL/g/min, respectively, p = 0.03).
Univariate analysis showed a significant correlation be-
tween myocardial perfusion and cardiac index at 4-month
post-diet (r = 0.57, p = 0.002). Also, myocardial perfusion
at 4-month was negatively associated to HTGC at the
same time point (r = −0.74, p = 0.001). Interestingly, myo-
cardial perfusion at 4 months post-diet was also correlated
to HTGC at 3 months (r = −0.61, p = 0.01) and even 2
months post-diet (r = −0.64, p = 0.01) when no alteration
in perfusion was still observed (Table 2).
Figure 6 has been designed to summarize time course of
events observed in this study during 4 months of HFHSD.Table 2 Univariate analysis between myocardial perfusion andExendin-4 decreased triglyceride content levels and
improved cardiac function
In the third experimental protocol, we observed significant
changes of parameters at 4 months post diet, as describedTable 1 Univariate analysis between ectopic lipid accumulation
and cardiac parameters
MTGC 4 M HTGC 4 M
r p r p
CI - 0.60 0.02 −0.75 0.0009
sWtnD NS NS 0.61 0.01
sFS NS NS 0.61 0.01in the previous experimental protocol. Indeed, mice be-
came significantly obese with increased AUC of glucose
during glucose tolerance test (Fig. 7Ai, Bi, Ci and Di).
They displayed higher TG accumulation both in the heart
and the liver (Fig. 7Ei and Fi). These abnormalities were
again accompanied by significant impairments of cardiac
function parameters (Fig. 7Hi, Ii and Ji).
Furthermore, 14 days post-treatment with Ex 4 sig-
nificantly decreased fasting plasma glucose and AUC
glucose after GTT (Fig. 7Aii, Aiii, Bii, Biii, Cii and Ciii).
Insulin level measured after sacrifice of the animals was
significantly higher in HFHSD group treated with Ex-4
(2.0 ± 0.3 ng/mL) compared to placebo-treated HFHSD
group (1.30 ± 0.15 ng/mL) and SD group (0.35 ± 0.05
ng/mL) (Additional file 3).
Bi-injection daily treatment with Exendin-4 (Ex-4) or
Placebo resulted in a −9.6 ± 1.5 % and −4.3 ± 0.6 % signifi-
cant small weight loss respectively (Fig. 7Dii and Diii).
Significant higher VAT (+57 %) and SCAT (+26 %) wasectopic fat accumulation or cardiac dysfunction
Myocardial perfusion
r P
CI 4 M 0.57 0.002
HTGC 4 M - 0.74 0.001
HTGC 3 M - 0.61 0.01
HTGC 2 M - 0.64 0.01
MTGC 4 M - NS
Fig. 6 Time course of events. Time course illustration showing time points of abnormalities’ onset associated to HFHSD-induced obesity and type
2 diabetes mice model. Quantitative MR parameters allowed calculation of percentage of change compared to SD-control mice. HTGC: Hepatic
triglyceride content, MTGC: myocardial triglyceride content, IPGTT: intraperitoneal glucose tolerance test, IPITT: intraperitonal insulin tolerance test, FPG:
Fasting plasma glucose, Wth: Wall thickness, CI: cardiac index, sFS: Septum fractional shortening
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change in fat mass body composition was observed
after Ex-4 treatment (data not shown).
Ex-4 significantly decreased both myocardial and hep-
atic triglyceride content after only two weeks of treat-
ment whereas placebo-treated mice did not (Fig. 7Eii,
Eiii, Fii and Fiii). Furthermore, percentage of MTCG and
HTGC decreases are significantly higher in treated mice
compared to placebo (57.8 ± 4.9 % vs 2.5 ± 19.7 %, p =
0.02; and 71.2 ± 4.0 % vs. 0.2 ± 16.1 %, p < 0.0001).
More interestingly, in multivariate analysis, hepatic TG
decrease was independent of weight loss and glucose
levels decrease and only linked to treatment (Table 3).
Plasma triglyceride measurements in HFHSD mice
showed significant higher plasma triglycerides compared
to SD mice (90.87 ± 24.03 vs 52.28 ± 7.91, p = 0.0009)
(Fig. 7Gi). Short time exendin-4 treatment had no effect
on these triglycerides levels (Fig. 7Gii and Giii)
Exendin-4 treatment significantly reduced the septal
thickness (Fig. 7Hii and Hiii) and increased the fractional
shortening (Fig. 7Iii and Iiii). The decrease in septal thick-
ness was correlated to treatment effect only (r = 0.42,
p = 0.04), and delta fractional shortening was independ-
ently associated to this treatment (Table 3).
We observed a strong alteration of the cardiac index
at 4-month post-diet (0.48 ± 0.04 μL/min/g in obese mice
vs. 0.72 ± 0.05 μL/min/g in control mice; p < 0.0001)(Fig. 7Ji). Impaired cardiac index observed in HFHSD
group was partly reversed by Ex-4 treatment (Fig. 7Jii and
Jiii) but remained significantly higher than in the control
group (p = 0.0005). Linear regression shows no link
between weight loss and CI improvement, or decrease
in AUC of Glucose.
We also found significant changes in myocardial per-
fusion at rest 4-month post diet, as observed in the first
part of the study at the 4-month time point analyzed
using unpaired t-test (Fig. 7Ki). Finally, short duration of
Ex-4 treatment also increased myocardial perfusion and
reached the SD group level (Fig. 7Kii and Kiii). Delta
perfusion was significantly correlated to treatment effect
and to glycemia improvement, but not to weight loss
(Table 3).
Discussion
Multimodal CMR allows the simultaneous evaluation of
different parameters and the correlation with different
information on specific cardiac pathologies. In human
studies it is possible to assess these parameters at one
time point and to follow changes in time, but it is diffi-
cult to study the development of the pathology from
early to late stage. Animal models offer the ability to do
such follow-ups in a well-monitored evolution of the dis-
ease. Here, we performed a robust multi-modal in vivo
MR protocol in mice including simultaneous assessment
Fig. 7 Four months diet effects on metabolic and cardiac parameters
were significantly reversed by Ex-4 treatment. Intraperitoneal Glucose
tolerance test showed elevated AUC glucose (ai, bi) and fasting plasma
glucose (ci) after M4 of HFHSD. Ex-4 significantly improved glucose
secretion compared to placebo mice (aii, aiii, bii, biii) and reduced fasting
plasma glucose in both placebo (cii), and Ex-4 groups (ciii). Ex-4
treatment induced significant weight loss in both placebo (dii) and Ex-4
groups (diii) as well. Cardiac and hepatic fat accumulations are increased
in obese mice (ei, fi) and short duration of Ex-4 treatment dramatically
reduced both ectopic lipid accumulation (eiii, fiii) whereas no change
was observed in saline-treated mice (eii, fii). However, Ex-4 treatment had
no effect on plasma triglyceride levels (gii, giii) albeit significant increase
4-month post-diet in HFHSD group (gi). Cardiac parameters altered with
HFHSD (hi, ii, ji) are significantly corrected after Ex-4 treatment (hiii, liii, jiii)
but not after saline treatment (hii, lii, jii). sWthD: Septum wall thickness,
sFS: Septum fractional shortening, CI: Cardiac index. HFHSD mice
displayed hypoperfusion at 4-month (ki) which is completely corrected
after Ex-4 treatment (kiii) compared to placebo group (kii). Data
are presented as means ± SEM. Treatment effect on AUC glucose during
IPGTTT was assessed using Two-way ANOVA test. Other parameters were
statistically assessed with paired t-test or Wilcoxon signed rank test
when values were not normally distributed. *p <0,05; **p <0,005;
***p <0,0005
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tion of lipid accumulation in both heart and liver within
reasonable scan- and post-processing-time. We showed
early-elevated hepatic triglyceride content at one-month
post-HFHSD, followed by elevated myocardial triglyceride
content at two months. Impairments of cardiac function
and myocardial perfusion were measurable at 3 and 4
months. Finally, these abnormalities were partially or to-
tally reversed after 14-day treatment with Exendin-4.
Both intra-cardiac and intra-hepatic triglyceride con-
tent have been validated against biochemical assay by
others [17, 40]. In this current study, we verified that the
difference in TG content in the heart and the liver be-
tween HFHSD and SD groups shown by MR spectros-
copy agreed with difference observed using in vitro
biochemical assay measurement. Furthermore, our 1H-
MRS and biochemical estimates are consistent with
values reported in other studies [41–43].
To our knowledge, there is no in vivo animal study in-
vestigating both heart and liver lipid content simultan-
eously in the context of the development of obesity and
diabetes.
Weight follow-up, glucose tolerance test and insulin
tolerance test confirmed that the HFHSD mice devel-
oped obesity and impairment of glucose homeostasis
within the experimental time course when compared to
SD mice as described by others [44]. Both cardiac and
liver steatosis in obesity and diabetes have been de-
scribed in human and animal studies [9–11], highlight-
ing the potential effects of these conditions on the heart.
However little is known on the time course of TG accu-
mulation in heart and liver during the development of
the disease and on their correlation with myocardial
Table 3 Multiple linear regression analysis using delta HTGC and delta MTGC as the dependant variables, and delta glycemia,
weight loss and treatment as independent variables
Dependant variable Variables entered in the models Total R Reg. P value ß coefficient t Sig.
Delta HTGC Weight loss 0.76 0.0005 0.31 1.7 0. 10
Delta AUC Glucose 0.26 1.5 0.15
Treatment 0.41 2.0 0.05
Delta sFS Delta AUC Glucose 0.57 0.02 −0.04 −0.2 0.85
Treatment −0.54 −2.6 0.018
Delta Perfusion Delta Glycemia 0.54 0.04 −0.32 −1.4 0.18
Treatment −0.29 −1.3 0.23
Delta = Value before treatment – Value after treatment
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showed early TG accumulation in liver and heart. More-
over, TG accumulation in the liver preceded that of the
heart suggesting pivotal involvement of hepatic insulin
resistance in the development of metabolic complica-
tions of obesity. Another relevant observation is that al-
though we found a significant correlation between both
hepatic and cardiac fat accumulation, linear regression
showed an important disparity between both tissue TG
accumulations. These combined data strengthen our
hypothesis regarding a tissue specific mobilization of
ectopic fat development based on data obtained in pa-
tients. Indeed, obese patients have different phenotype of
ectopic fat accumulation. While some patients exhibit ele-
vated hepatic triglyceride content and normal pancreatic
triglyceride content level, others have increased cardiac
triglyceride content with normal hepatic triglyceride con-
tent. This indicates tissue-specific distribution of TG in
non-adipose tissue.
Furthermore, in our previous studies, we assessed ec-
topic fat modulation after weight loss in obese patients
who underwent bariatric surgery. Ectopic fat accumula-
tion did not respond equally. We observed a huge de-
crease of hepatic and pancreatic triglyceride contents
[10], accompanied by a moderate epicardial adipose tis-
sue reduction, and no change in myocardial triglyceride
content [45]. Moreover, percentages of ectopic fat
losses were neither correlated with each other, nor with
body mass change. This observation has also been de-
scribed by others [46], [47], which consolidates our
hypothesis.
As expected, myocardial and hepatic TG levels are sig-
nificantly linked to weight, glycemia and AUC glucose
during IPGTT. Negative correlation of both hepatic and
myocardial triglyceride content with cardiac function
was observed in our study. This result is in agreement
with other observations [48–50], and suggests that a po-
tentially lipotoxic effect of steatosis may contribute to sub-
clinical alteration of myocardial function. However, we
also found a significant association between perfusion and
TG accumulation unlike Korosoglou's findings [49].The exact mechanisms by which steatosis causes car-
diac dysfunction is unclear, however an increasing num-
ber of reports suggest that lipotoxicity results from
imbalance between cardiac lipids uptake and β-
oxidation. Persistent increase of β-oxidation due to ex-
cess lipids availability may lead to toxic intermediate lipid
intermediates production such as ceramides and diacyl-
glycerol, which could interfere with cardiac signaling cas-
cade and induce cell apoptosis [51–53]. These early
abnormalities induced greater reactive oxygen species pro-
duction [54, 55]. In this oxidative stress environment com-
bined with increased inflammation [56, 57], calcium
homeostasis could be affected resulting in excitation-
contraction coupling alteration and therefore to myocar-
dial contractile dysfunction [58]. Increased intermyocellu-
lar fibrosis resulting from collagen stacked in extra-
cellular matrix is frequently associated to cardiac steatosis
observation, and could be responsible for tissue stiffness,
reducing diastolic relaxation [59, 60]. In the longer term,
cardiac energetics could be affected as well, accompanied
by inefficient mitochondrial ATP production [61]. Involve-
ment of the renin-angiotensin system and more recently
micro-RNAs has also been described [56, 62–64].
Cine MRI showed late alteration of systolic function
as reported by Nagarajan et al. [65], and others [6, 13,
66, 67]. However, conflicting results exist in the litera-
ture regarding early cardiac dysfunction in metabolic
alterations [68–70]. Differences in experimental condi-
tions such as the animal model, the duration of experi-
ments, or the diet composition may explain these
discrepancies. It would be interesting to delve into
cardiac function in this model with the measurement
of other parameters such as mitral peak velocity [68,
69] and regional myocardial function as well (strain,
torsion, and synchrony) which may be reduced earlier,
before impairment of global cardiac parameters [71].
We did not explore regional cardiac dysfunction, but
we measured the thickness of different parts of the
myocardial wall as described by others [72] and found
a significant higher wall thickness in mice fed a
HFHSD.
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non-invasive arterial spin labeling technique that could
be applied in each mouse repetitively in a reduced scan
time [28, 73]. Although no significant difference was ob-
served using two way ANOVAs test with repeated mea-
sures which includes time effect in the follow-up study
statistical analysis; a significantly diminished myocardial
perfusion in HFHSD mice was observed at 4-month in
experimental protocol 3. This difference is consistent
with the result obtained when the 4-month time point is
analyzed alone in experimental protocol 2. Previous
studies on small animals have examined myocardial per-
fusion at baseline and under various conditions includ-
ing myocardial infarction [74], vasodilator stress [75],
anesthesia [20] transgenic mice [76] and in non-obese
diabetic rat hearts [77]. In a recent study, Naresh NK
et al. have used first-pass MBF measurements under rest
and regadenoson stress in a high-fat diet obesity mouse
model [78]. They found no difference in myocardial
blood flow (MBF) at rest between control and obese
mice, but evidenced a reduced adaptation of flow during
stress. In our study, we performed a longitudinal assess-
ment of myocardial perfusion during 4 months of HFHSD
and showed a significant alteration of basal perfusion, but
under isoflurane anesthesia. Isoflurane anesthesia is a
known vasodilator and might have caused herein a light
stress condition eliciting perfusion differences between
controls and HFHSD animals [79]. This is supported by
the fact that all perfusion values found in this study are
comparatively high. The reduced perfusion measured
under isoflurane may therefore be due to endothelial
dysfunction in response to interrelated chronical ROS
production, inflammatory state, reduced nitric oxide
bioavailability, and ceramides [80–83]. Microcirculation
remodeling implying possible interstitial or perivascular
fibrosis as shown in humans by Chiribiri [84] could be also
involved. Additional investigations including pharmaco-
logic stress will be useful for a complementary under-
standing of microvascular functional defects in diabetic
cardiomyopathy.
In the second protocol, we studied the short-term
effect of Exendin 4 treatment on ectopic fat depots de-
velopment and cardiovascular alterations. Exendin-4, a
glucagon-like peptide-1 (GLP-1) receptor agonist is
among those treatments of type 2 diabetes that lower
blood glucose level by increasing glucose-dependent
insulin secretion and suppressing excess glucagon se-
cretion [85]. It reduces weight as well by inducing sati-
ety. GLP-1 and GLP-1 receptor (GLP-1R) agonists are
considered as beneficial for cardiovascular function
[28–30, 86, 87] given that they improve biomarkers of
cardiovascular risk, decrease systolic blood pressure,
improve endothelial function and display beneficial ac-
tions on acute ischemic myocardial damage [88].Placebo and ex-4 treated mice groups displayed a sig-
nificant weight loss after 15 days of treatment with no
change in diet composition. This effect seems to be
mainly due to stress-induced by bi-injection daily rather
than to treatment, especially in placebo group.
Our work demonstrates that a short treatment with
Exendin-4 improves myocardial function parameters and
increases myocardial perfusion. This effect was linked to
treatment and decreased glycaemia throughout multi-
variate analysis.
Fractional shortening and cardiac perfusion increased
beyond the level of SD controls. Significant overcompen-
sation has been verified by statistical analysis of GLP-1
response versus SD levels. Comparison between HFHSD
post-GLP-1 treatment with SD groups showed no sig-
nificant difference in myocardial perfusion (p = 0.12). By
contrast, fractional shortening was significantly higher
after GLP-1 treatment compared to SD controls (p =
0.009). We don’t have any specific explanation for this
observation.
A comparable beneficial effect of GLP-1 on vascular
function was previously shown in peripheral vessels,
when GLP1 administration enhanced insulin mediated
forearm blood flow responses to ACh [28, 89]. In swine,
GLP-1 infusion during 4 h attenuates post-resuscitation
myocardial microcirculatory dysfunction [90]. In
humans, the effect of GLP-1 agonist on perfusion is de-
bated. In healthy overweight volunteers, acute exenatide
infusion increases capillary perfusion via nitric oxid in-
dependent pathway [91]. In a small study of eight T2D
male without coronary artery disease, exenatide induced
an increase in myocardial blood flow evaluated by PET,
without changing myocardial glucose uptake [92]. Never-
theless, this effect is missing in Faber R’s work [93].
We found also that short-term GLP-1 treatment dras-
tically diminished both cardiac and hepatic steatosis
whereas it had no effect on plasmatic triglycerides. This
important effect after such a short administration is
impressive and contrasts with the small impact of the
treatment on both weight and glycemia. This result em-
phasizes the data of Monji et al. who reported that 40
days treatment with Exendin-4 reduced ceramide stain-
ing in two mouse models of diabetes [32].
The impact of GLP-1 treatment in cardiac steatosis
has not been evaluated in humans. Furthermore, there is
limited information on the impact of GLP-1 analog on
real life patient [94], and the long term effect of GLP-1
agonist in diabetic cardiomyopathy is unknown.
Conclusion
To our knowledge, this is the first longitudinal study in-
volving CMR multimodal imaging in diet induced obese
mice showing early increase in hepatic and cardiac steato-
sis preceding alteration of perfusion and cardiac function.
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Exendin-4 on cardiac parameters and both hepatic and
cardiac steatosis. The sequence of events elicited in the de-
velopment of the cardiometabolic disease in mice as well
as the effect of exendin-4 on cardiac steatosis are of poten-
tial interest to build diagnostic and therapeutic strategies
in humans.
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